Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.14USD
28 Jul 2016
Change (% chg)

$0.00 (+0.59%)
Prev Close
$0.14
Open
$0.14
Day's High
$0.14
Day's Low
$0.13
Volume
625,197
Avg. Vol
591,970
52-wk High
$0.20
52-wk Low
$0.06

Summary

Name Age Since Current Position

William Mitchell

80 2016 Chairman of the Board

Thomas Equels

62 2016 President, Chief Executive Officer

Adam Pascale

2016 Chief Financial Officer

Wayne Springate

44 2011 Senior Vice President - Operations

David Strayer

69 2016 Chief Scientific Officer

Peter Rodino

64 2016 Lead Director

Charles Jones

2012 Associates Public Relations

Biographies

Name Description

William Mitchell

Dr. William M. Mitchell, M.D., Ph.D., is Chairman of the Board of the Company. Dr. Mitchell, who has been an independent Director since July 1998, is Professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine and is a board certified physician. Mitchell earned an M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as an Osler House Officer in Internal Medicine at the Johns Hopkins Hospital, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews, and scientific meeting abstracts that relate to viruses, anti-viral drugs, immune responses to microbial infection including HIV and C.pneumoniae, genetic based cancer diagnostics (i.e.- the liquid biopsy), and other biomedical topics. He has worked for and with many professional societies including the American Society of Investigative Pathology (ASIP), the International Society for Antiviral Research (ISAR), the American Society of Biochemistry and Molecular Biology (ASBMB), the American Chemical Society (ACS), the American Society of Microbiology (ASM), and the American Society of Clinical Oncology (ASCO). Mitchell is a member of the American Medical Association (AMA). He has served on numerous National Institutes of Health (NIH) review committees as well as the Centers for Disease Control (CDC) and the College of American Pathologists (CAP). Mitchell previously served as a Director with the Company from 1987 to 1989. Mitchell serves also on the Board of Directors of Chronix Biomedical, Inc., an international molecular diagnostic company.

Thomas Equels

Mr. Thomas K. Equels Esq., is President, Chief Executive Officer of the Company. Equels has served as Executive Vice Chairman, Chief Financial Officer, Secretary and General Counsel of Hemispherx. Equels’ experience and education provide a firm basis for his executive service. For more than thirty years his legal practice focused on complex business litigation, including cases related to corporate finance and market issues. For example, in 2008 he won Florida’s highly coveted “Most Effective Lawyer” award in the “Complex Business Litigation” category based upon obtaining for the Delaware Insurance Commissioner a $26.8 million judgment against Bear Stearns in a case which unraveled Bear Stearns’ abuses related to CMOs, a complex financial instrument. In a rare feat, that same year he also was awarded “Most Effective Lawyer” in the appellate category for a Florida Supreme Court win in an important medical records access case with major constitutional implications. Equels also has extensive experience in international matters; for example he has served for many years as international counsel for the Republic of Panama and also as litigation counsel for the People’s Republic of China’s Chinese National Petroleum Corp. He has worked extensively in Europe, as well as in South America, Asia and Africa. Equels received his Juris Doctor degree Magna Cum Laude from Florida State University and is a Bachelor of Science Summa Cum Laude graduate of Troy University, where he also received a management related Master of Science Degree.

Adam Pascale

Mr. Adam Pascale CPA, is Chief Financial Officer of the Company. Mr. Pascale has been employed with Company for 18 years, with more than two decades of public accounting experience and prior public company experience. He earned a Bachelor of Arts degree in Accounting and Finance from Rutgers University. Mr. Pascale served for several years as a CPA prior to joining Hemispherx, and is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants.

Wayne Springate

Mr. Wayne S. Springate is Senior Vice President - Operations of Hemispherx Biopharma Inc. Mr. Springate joined Hemispherx in 2002 as Vice President of Business Development when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facilities. He led the consolidation of our Rockville facility to our New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to our production facility in New Brunswick. He was also responsible for preparing and having a successful Preapproval Inspection by the FDA for our New Brunswick manufacturing plant in connection with the filing of our Ampligen® NDA. Currently he is managing a capital improvement budget to enhance our Alferon® facility in accordance with cGMP. Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.

David Strayer

Dr. David R. Strayer, M.D., is Chief Scientific Officer of the Company. He has been the Company’s Medical Director since 1986. Strayer, based upon this experience, is the foremost medical expert on Ampligen and Alferon in the World. He served as a Professor in the Department of Neoplastic Diseases and the Department of Medicine at the Medical College of Pennsylvania and at Hahnemann University from 1987 to 1998. He is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Strayer has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. He attended the School of Medicine at the University of California at Los Angeles where he earned a Doctor of Medicine degree in 1972.

Peter Rodino

Mr. Peter W. Rodino III, Esq., is Lead Director of Hemispherx Biopharma, Inc. Mr. Rodino's appointment was the result of the resignation of Richard C. Piani due to health reasons. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. For the past 17 years, as founder and president of Rodino Consulting, Mr. Rodino has provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.

Charles Jones

Basic Compensation

Name Fiscal Year Total

William Mitchell

--

Thomas Equels

1,668,450

Adam Pascale

--

Wayne Springate

344,164

David Strayer

367,334

Peter Rodino

--

Charles Jones

--
As Of  30 Dec 2014